Business highlights in Q2 2024
- In April the company announced the publication of pudafensine preclinical pharmacology results in the British Journal of Pharmacology
Business highlights after this reporting period
- In July the company announced the publication of the international patent application regarding pudafensine’s dosage regime for the treatment of erectile dysfunction
Financial Highlights
| Second Quarter (2024-04-01 – 2024-06-30) |
| Net revenue were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -4,991 (-8,882) |
| Earnings per share before and after dilution was DKK –0.09 (-0.20) |
| Cash: TDKK 14,487 (25,935) |
| Solidity: 94% (45%) |
| First Six Months (2024-01-01 – 2024-06-30) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -8,568 (-17,559) |
| Earnings per share before and after dilution was DKK –0.16 (-0.38) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/